Abstract:Objective To explore the risk factors of skeletal-related events (SREs) and their influence on the survival of breast cancer patients with bone metastases.Methods Relevant clinical data and outcomes of 123 female breast cancer patients with bone metastases in Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital between January 2010 and June 2017 were retrospectively reviewed. All patients were divided into SREs group or non-SREs group according to whether SREs occurred at the last follow-up. The clinical features, including age, pathology, molecular characteristics of breast cancer, axillary lymph node metastasis, bone metastasis interval, and number of bone metastasis, were analyzed and compared between two groups. Univariate and multivariate analysis were performed using chi-square test and logistic regression analysis to explore the risk factors for SREs. The prognosis survival difference between the two groups was analyzed by Kaplan-Meier test.Results One hundred and twenty-three consecutive patients with the average age of (53.9±11.3) years (range, 23-78 years) were identified during study period.The number of patients with SREs or non-SREs was 61 cases and 62 cases. There were significant differences in the number of axillary lymph nodes bone metastasis interval, outside the bone metastasis and the number of bone metastases (all P values<0.1), between the two groups, but the age, tumor grade, hormone receptor status, histological type, visceral metastases were not statistically significant(all P values>0.05). Multivariate analysis showed that the difference of lymph node metastasis and multiple bone metastasis between the two groups was statistically significant(all P values<0.05). Totally, the group of SREs occurred SREs. The frequency of SREs occurrence from high to low in SREs group was radiation therapy for bone metastases (n=34, 35.8%), pathological fracture (n=32, 33.7%), spinal cord compression (n=13, 13.7%), surgery for bone lesion (n=9, 9.5%), hypercalcemia (n=7, 7.4%). Survival analysis showed the median survival time of non-SREs group and SREs group were 54 months and 35 months respectively, and the difference was statistically significant (P<0.05).Conclusions Axillary lymph node metastases and multiple bone metastases are independent risk factors for SREs, and SREs indicate poor prognosis in breast cancer patients with bone metastases.
何沁, 臧仕昭, 鲍其远, 沈宇辉, 张伟滨. 乳腺癌骨转移发生骨相关事件的危险因素及其对患者生存期的影响[J]. 中华解剖与临床杂志, 2019, 24(3): 245-249.
He Qin, Zang Shizhao, Bao Qiyuan, Shen Yuhui, Zhang Weibin. The risk factors of skeletal-related events and their influence on survival in breast cancer patients with bone metastases. Chinese Journal of Anatomy and Clinics, 2019, 24(3): 245-249.
Harries M, Taylor A, Holmberg L, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients[J]. Cancer Epidemiol, 2014, 38(4): 427-434. DOI:10.1016/j.canep.2014.05.005.
[2]
Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of US. Medicare beneficiaries, 1999-2006[J]. Breast Cancer Res Treat, 2012, 131(1): 231-238. DOI:10.1007/s10549-011-1721-x.
[3]
Yong M, Jensen AÖ, Jacobsen JB, et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)[J]. Breast Cancer Res Treat, 2011, 129(2): 495-503. DOI:10.1007/s10549-011-1475-5.
[4]
Yamashiro H, Takada M, Nakatani E, et al. Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan[J]. Int J Clin Oncol, 2014, 19(5): 852-862. DOI: 10.1007/s10147-013-0643-5.
[5]
Ulas A, Bilici A, Durnali A, et al. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases[J]. Tumour Biol, 2016, 37(1): 1131-1140. DOI:10.1007/s13277-015-3907-z.
[6]
Yanae M, Fujimoto S, Tane K, et al. Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid[J]. J Bone Oncol, 2017, 8: 18-22. DOI:10.1016/j.jbo.2017.08.004.
[7]
van der Pol CB, Schweitzer ME, Di Primio G, et al. Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival[J]. Breast Cancer Res Treat, 2014, 146(3): 583-589. DOI:10.1007/s10549-014-3046-z.
[8]
Klaassen Z, Howard LE, de Hoedt A, et al. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer[J]. Cancer, 2017, 123(9): 1528-1535. DOI:10.1002/cncr.30505.
[9]
Rosa Mendoza ES, Moreno E, Caguioa PB. Predictors of early distant metastasis in women with breast cancer[J]. J Cancer Res Clin Oncol, 2013, 139(4): 645-652. DOI:10.1007/s00432-012-1367-z.
[10]
Sciubba DM, Goodwin CR, Yurter A, et al. A systematic review of clinical outcomes and prognostic factors for patients undergoing surgery for spinal metastases secondary to breast cancer[J]. Global Spine J, 2016, 6(5): 482-496. DOI:10.1055/s-0035-1564807.
[11]
Amoretti N, Diego P, Amélie P, et al. Percutaneous vertebroplasty in tumoral spinal fractures with posterior vertebral wall involvement: feasibility and safety[J]. Eur J Radiol, 2018, 104: 38-42. DOI:10.1016/j.ejrad.2018.04.010.
[12]
Aghayev K, Papanastassiou ID, Vrionis F. Role of vertebral augmentation procedures in the management of vertebral compression fractures in cancer patients[J]. Curr Opin Support Palliat Care, 2011, 5(3): 222-226. DOI:10.1097/SPC.0b013e328349652d.
[13]
Katakami N, Kunikane H, Takeda K, et al. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage ⅢB and Ⅳ lung cancer-CSP-HOR 13[J]. J Thorac Oncol, 2014, 9(2): 231-238. DOI:10.1097/JTO.0000000000000051.
[14]
Irelli A, Cocciolone V, Cannita K, et al. Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer[J]. Bone, 2016, 87: 169-175. DOI:10.1016/j.bone.2016.04.006.
[15]
Ding X, Fan Y, Ma F, et al. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis[J]. Breast, 2012, 21(4): 544-549. DOI:10.1016/j.breast.2012.04.008.